Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.

J Thorac Oncol

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado. Electronic address:

Published: April 2021

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.12.022DOI Listing

Publication Analysis

Top Keywords

lorlatinib considered
4
considered preferred
4
preferred first-line
4
first-line option
4
option patients
4
patients advanced
4
advanced alk
4
alk rearranged
4
rearranged nsclc
4
lorlatinib
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!